Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtors Turnover Ratio Ratio ・Standalone data |
|
||||
| Headcount (Total Employees) Number ・Standalone data |
|||||
| Key Product Dispatch Quantity - N-Butyl Lithium (NBL) kgs ・Standalone data |
|||||
| Net Capital Turnover Ratio Ratio ・Standalone data |
|||||
| Total Number of Batches Produced Number ・Standalone data |
|||||
| Total Production Volume (Quantity Dispatched) kgs ・Standalone data |
|||||
Documents
Announcements
- Closure of Trading Window 30 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Feb - Copies of Un-audited standalone financial results of the company for the Third quarter and Nine months ended on December 31, 2025 published in following Newspapers …
- Unaudited Standalone Financial Results Along With The Limited Review Report For The Period Ended On December 31, 2025 14 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday, February 14, 2026 As Required Under Regulation 30 Of SEBI (LODR) Regulations, 2015
14 Feb - Board approved Q3 and nine-month unaudited results to Dec 31, 2025; limited review unqualified; vendor payments ratified.
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 11 Feb
Product Profile:
a) API Intermediates:[1] Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine
b) Fine Chemicals and Reagents:[2] IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, Aminouracil, etc.